These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 33415499)

  • 1. Letter to the editor: Model-based simulation to support the extended dosing regimens of atezolizumab.
    Wu B; Liu SN; Ballinger M; Sternheim N; Patel H; Mazieres J; Bruno R
    Eur J Clin Pharmacol; 2021 Jul; 77(7):1065-1066. PubMed ID: 33415499
    [No Abstract]   [Full Text] [Related]  

  • 2. Authors' reply to letters to the editor "model-based simulation to support the extended dosing regimens of atezolizumab".
    Chou CH; Hsu LF
    Eur J Clin Pharmacol; 2021 Jul; 77(7):1067-1068. PubMed ID: 33237384
    [No Abstract]   [Full Text] [Related]  

  • 3. Letter to the editor: Comments on 'A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation'.
    Diekstra MHM; Malmberg R; Sleijfer S; van Leeuwen RWF
    Eur J Cancer; 2020 Oct; 138():54-56. PubMed ID: 32854077
    [No Abstract]   [Full Text] [Related]  

  • 4. Alternative dosing regimens for atezolizumab: an example of model-informed drug development in the postmarketing setting.
    Morrissey KM; Marchand M; Patel H; Zhang R; Wu B; Phyllis Chan H; Mecke A; Girish S; Jin JY; Winter HR; Bruno R
    Cancer Chemother Pharmacol; 2019 Dec; 84(6):1257-1267. PubMed ID: 31542806
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alternative dosing regimens for atezolizumab: right dose, wrong frequency.
    Goldstein DA; Ratain MJ
    Cancer Chemother Pharmacol; 2019 Dec; 84(6):1153-1155. PubMed ID: 31630223
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reply to Francesco Massari and Vincenzo Di Nunno's Letter to the Editor re: Jose Luis Perez-Gracia, Yohann Loriot, Jonathan E. Rosenberg, et al. Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens. Eur Urol 2018;73:462-8.
    Perez-Gracia JL
    Eur Urol; 2018 Jul; 74(1):e14. PubMed ID: 29656856
    [No Abstract]   [Full Text] [Related]  

  • 7. Reply to Satoshi Funada, Takashi Yoshioka, and Yan Luo's Letter to the Editor re: Ashley M. Hopkins, Ganessan Kichenadasse, Christos S. Karapetis, et al. Concomitant Antibiotic Use and Survival in Urothelial Carcinoma Treated with Atezolizumab. Eur Urol 2020;78:540-3.
    Hopkins AM; Kichenadasse G; Sorich MJ
    Eur Urol; 2020 Dec; 78(6):e227. PubMed ID: 32958298
    [No Abstract]   [Full Text] [Related]  

  • 8. Comparative Effectiveness of Non-cisplatin First-line Therapies for Metastatic Urothelial Carcinoma: Phase 2 IMvigor210 Study Versus US Patients Treated in the Veterans Health Administration.
    Vander Velde N; Guerin A; Ionescu-Ittu R; Shi S; Wu EQ; Lin SW; Hsu LI; Saum KU; de Ducla S; Wang J; Li S; Thåström A; Liu S; Shi L; Leppert JT
    Eur Urol Oncol; 2019 Feb; 2(1):12-20. PubMed ID: 30929841
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population pharmacokinetics, exposure-safety, and immunogenicity of atezolizumab in pediatric and young adult patients with cancer.
    Shemesh CS; Chanu P; Jamsen K; Wada R; Rossato G; Donaldson F; Garg A; Winter H; Ruppel J; Wang X; Bruno R; Jin J; Girish S
    J Immunother Cancer; 2019 Nov; 7(1):314. PubMed ID: 31753029
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab-Letter.
    Goldstein DA; Ratain MJ
    Clin Cancer Res; 2020 May; 26(10):2435. PubMed ID: 32414762
    [No Abstract]   [Full Text] [Related]  

  • 11. Cost-effectiveness of second-line atezolizumab in Canada for advanced non-small cell lung cancer (NSCLC).
    Ondhia U; Conter HJ; Owen S; Zhou A; Nam J; Singh S; Abdulla A; Chu P; Felizzi F; Paracha N; Sangha R
    J Med Econ; 2019 Jul; 22(7):625-637. PubMed ID: 30836031
    [No Abstract]   [Full Text] [Related]  

  • 12. Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial.
    Eng C; Kim TW; Bendell J; Argilés G; Tebbutt NC; Di Bartolomeo M; Falcone A; Fakih M; Kozloff M; Segal NH; Sobrero A; Yan Y; Chang I; Uyei A; Roberts L; Ciardiello F;
    Lancet Oncol; 2019 Jun; 20(6):849-861. PubMed ID: 31003911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atezolizumab Plus Nab-paclitaxel in PD-L1-Positive TNBC-Letter.
    Bravaccini S; Ravaioli S; Tumedei MM; Rocca A; Palleschi M; Puccetti M; Parrella P; Altini M; Maltoni R
    Clin Cancer Res; 2020 Jul; 26(14):3892-3893. PubMed ID: 32669274
    [No Abstract]   [Full Text] [Related]  

  • 14. Comparison of intravenous and subcutaneous exposure supporting dose selection of subcutaneous belimumab systemic lupus erythematosus Phase 3 program.
    Yapa SW; Roth D; Gordon D; Struemper H
    Lupus; 2016 Nov; 25(13):1448-1455. PubMed ID: 27072354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retreatment With Anti-PD-L1 Antibody in Advanced Non-small Cell Lung Cancer Previously Treated With Anti-PD-1 Antibodies.
    Fujita K; Uchida N; Yamamoto Y; Kanai O; Okamura M; Nakatani K; Sawai S; Mio T
    Anticancer Res; 2019 Jul; 39(7):3917-3921. PubMed ID: 31262921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial.
    Mittendorf EA; Zhang H; Barrios CH; Saji S; Jung KH; Hegg R; Koehler A; Sohn J; Iwata H; Telli ML; Ferrario C; Punie K; Penault-Llorca F; Patel S; Duc AN; Liste-Hermoso M; Maiya V; Molinero L; Chui SY; Harbeck N
    Lancet; 2020 Oct; 396(10257):1090-1100. PubMed ID: 32966830
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of atezolizumab versus docetaxel and nivolumab in the treatment of non-small cell lung cancer as a second line in France.
    Marine S; Stéphane R; Nicolas P; Felizzi F; Paracha N; Benjamin M; Perol M
    J Med Econ; 2020 May; 23(5):464-473. PubMed ID: 31951770
    [No Abstract]   [Full Text] [Related]  

  • 18. AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer.
    Antoniotti C; Borelli B; Rossini D; Pietrantonio F; Morano F; Salvatore L; Lonardi S; Marmorino F; Tamberi S; Corallo S; Tortora G; Bergamo F; Brunella DS; Boccaccino A; Grassi E; Racca P; Tamburini E; Aprile G; Moretto R; Boni L; Falcone A; Cremolini C
    BMC Cancer; 2020 Jul; 20(1):683. PubMed ID: 32698790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prolonged In-use Stability of Diluted Atezolizumab in Commercial Intravenous Bags.
    Hui A; Yin J; Liu W; Zheng K
    Int J Pharm Compd; 2021; 25(3):246-257. PubMed ID: 34125716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population Pharmacokinetic and Pharmacokinetic/Pharmacodynamic Modeling of Weight-Based Intravenous Reslizumab Dosing.
    Passarell J; Jaworowicz D; Ludwig E; Rabinovich-Guilatt L; Cox DS; Levi M; Garin M; Fiedler-Kelly J; Bond M
    J Clin Pharmacol; 2020 Aug; 60(8):1039-1050. PubMed ID: 32333684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.